+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Gastroesophageal Junction Carcinoma Drug"

Gastroesophageal Junction Carcinomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Gastroesophageal Junction Carcinomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 142 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

Gastroesophageal Junction Carcinoma (GEJC) is a type of cancer that affects the junction between the esophagus and the stomach. It is a rare form of cancer, but is becoming increasingly common due to lifestyle changes and environmental factors. Treatment for GEJC typically involves a combination of chemotherapy, radiation therapy, and surgery. Drug therapies are also used to treat the disease, including targeted therapies, immunotherapies, and hormone therapies. The Gastroesophageal Junction Carcinoma Drug market is a rapidly growing segment of the Gastrointestinal Drugs market. It is driven by the increasing prevalence of GEJC, as well as the development of new and innovative treatments. Companies in this market include AstraZeneca, Merck, Pfizer, Roche, and Novartis. Show Less Read more